

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on October 30, 2008.

Frank C. Eisenschenk  
Frank C. Eisenschenk, Ph.D., Patent Attorney

REQUEST FOR CERTIFICATE OF  
CORRECTION UNDER 37 CFR 1.322  
AND 37 CFR 1.323  
Docket No. MDH.100XC1T

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Richard W. Voellmy  
Issued : July 29, 2008  
Patent No. : 7,405,080  
For : Compositions and Methods Relating to Prevention of Chemotherapy-Induced Alopecia

Mail Stop Certificate of Corrections Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION  
UNDER 37 CFR 1.322 (OFFICE MISTAKE)  
UNDER 37 CFR 1.323 (APPLICANT MISTAKE)

Sir:

A Certificate of Correction for the above-identified patent has been prepared and is attached hereto.

In the left-hand column below is the column and line number where errors occurred in the patent. In the right-hand column is the page and line number in the application where the correct information appears.

**Patent Reads:**

Column 11, line 37:

“being thought by”

**Application Should Read:**

Page 14, lines 6-7:

--being treated by--

**Patent Reads:**Column 12, line 35:

“acetaminophen”

**Patent Reads:**Column 16, line 43:

“in a area of skin”

Column 16, line 58:

“to a an appropriate”

Column 22, line 21:

“morphology”

**Application Reads:**Page 15, line 14:

--acetaminophen--

**Application Should Read:**Page 20, line 23:

--in an area of skin--

Page 20, lines 31-32:

--to an appropriate--

Page 27, line 34:

--morphology--.

A true and correct copy of page 15 of the specification as filed which support Applicant's assertion of the error on the part of the Patent Office accompanies this Certificate of Correction. Support for the correction at Column 11, line 37, can be found at Column 11, lines 16-44 where it is clear that the human patients or animals are being treated by a clinician or researcher.

The fee of \$100.00 was paid at the time this Request was filed. The Commissioner is also authorized to charge any additional fees as required under 37 CFR 1.20(a) to Deposit Account No. 19-0065.

Approval of the Certificate of Correction is respectfully requested.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/sl

Attachment: Copy of page 15 of the specification

human patient or animal that is being thought by a researcher or clinician. The term "effective dose" comprises any dose which, as compared to a corresponding hair follicle-containing tissue or human or animal subject which has not received such dose, results in increased resistance of hair follicles against killing by chemotherapeutic agents or in improved treatment, prevention, or severity reduction of chemotherapy-induced alopecia.

## INDUCERS

As discussed before, inducers of the stress protein response include physical inducers such as heat, UV radiation, electromagnetic field and chemical inducers such as heavy metal ions, e.g., Cd, Zn, Sn or Cu ions, other sulfhydryl-reactive compounds, e.g., sodium arsenite (an arsenic salt), inhibitors of energy metabolism, in particular inhibitors of mitochondrial function, amino acid analogs, e.g., canavanine or azetidine carboxylate, protein denaturants, e.g., ethanol and guanidinium hydrochloride, oxidizing agents, e.g., diamide, and other agents, e.g., toxicants that form protein adducts such as acetaminophen. Inducers also include inhibitors of proteolysis such as lactacystin and compounds that interfere with the proper function of an Hsp. Examples of the latter type of compound include benzoquinone ansamycins such as geldanamycin and herbimycin A that are known to specifically bind Hsp90 in its nucleotide-binding site. For a list of typical inducers see Zou et al. 1998. Cell Stress & Chaperones 3: 130-141. The above list is not exhaustive. Many additional chemicals are also known to be inducers of the stress protein response. Some of these chemicals including biclomol, cyclopentenones and certain prostaglandins do not appear to fit into any of the above-cited groups. Furthermore, there is little doubt that new chemical inducers will be discovered in the future, because, generally, any compound that has some degree of proteotoxicity will induce the stress protein response. Whether a particular compound will be proteotoxic may or may not be readily deduced from its structure. It seems therefore more appropriate to define chemical inducers functionally rather than structurally. For the purposes of this invention an inducer is a compound that is capable of enhancing Hsp expression at a sublethal concentration or is a sublethal physical condition that stimulates Hsp expression. There are many methods for discovering whether or not a compound/physical condition is an inducer. For example, parallel mammalian cell cultures can be exposed to a range of sublethal concentrations of a substance to be tested in the presence of a radiolabeled amino acid. After an appropriate exposure period, cells are harvested and lysed, and cell lysates are subjected to SDS-PAGE and autoradiography or fluorography. If the substance tested is a chemical inducer, it will enhance the rate of synthesis of polypeptides with molecular weights typical for Hsps (e.g., 90,70, 25-27 kDa). In a more rigorous version of the same test, a

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,405,080

Page 1 of 1

APPLICATION NO.: 09/939,161

DATED : July 29, 2008

INVENTOR : Richard W. Voellmy

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 11.

Line 37, "being thought by" should read --being treated by--.

Column 12.

Line 35, "acetaninophen" should read --acetaminophen--.

Column 16.

Line 43, "in a area of skin" should read --in an area of skin--.

Line 58, "to a an appropriate" should read --to an appropriate--.

Column 22.

Line 21, "morpohology" should read --morphology--.

MAILING ADDRESS OF SENDER:  
Saliwanchik, Lloyd & Saliwanchik  
P.O. Box 142950  
Gainesville, FL 32614-2950